Document is current

Article History

Received: 28 August 2020

Accepted: 22 December 2020

First Online: 4 February 2021

Ethics approval and consent to participate

: The study received ethical approval form the Yorkshire & The Humber - South Yorkshire Research Ethics Committee (Reference: 18/YH/0412) and research permissions from the Health Research Authority (Reference: 242712).

: Not applicable.

: SH is an employee and shareholder of Bristol Myers Squibb. KP is an employee of Bristol Myers Squibb. LG, DS, MH, JH are employees of Health Economics and Outcomes Research Ltd., Cardiff, UK, who received fees from Bristol Myers Squibb in relation to this study. EC has received research grants from Bio-Cancer, Biogen, Novartis, Pfizer, Roche, Sanofi and UCB, consultancy from Abbvie, Amgen, Biogen, Biocon, Chugai Pharma, Eli Lilly, Gilead, Janssen, Merck Serono, Novartis, Pfizer, Regeneron, Roche, R-Pharm and Sanofi, speakers fee from Amgen, Bristol Myers Squibb, Chugai Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Regeneron, Roche, Sanofi, and UCB. JRM has received consultancy fees from Abbvie, Eli Lilly, Pfizer and Bristol Myers Squibb and speaker fees from Pfizer, Bristol Myers Squibb and Novartis. SV and YP have no conflicts of interest to declare.